TTTomohiko Tairabune

Tomohiko Tairabune

*This is an algorithmically generated author record based on publicly available information.

Tomohiko Tairabune has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of Pharmacist-Led Educational Intervention on Switching to Generic Medicine Among Patients Using Brand-Name Medicines in Japan

    by Tomohiko Tairabune, Terutaka Goto, Kentaro Yamazaki, Kenzo Kudo, Ken-Ichi Sako, Tomoji Maeda, Takeshi Chiba

    The use of generic medicines (GEs) is being promoted to reduce healthcare costs. This study aims to evaluate the effect of a pharmacist-led educational intervention on the number of patients switching from brand-name medicines to GEs among patients who preferred brand-name products. Pharmacists provided a standardized explanation using pamphlets about GEs to patients who wished to use brand-name medicines and allocated time to answer questions. Basic knowledge about GEs (nine items) and perceptions of GE use (three items) were assessed before and after the intervention to determine whether changes influenced switching behavior. Between 1 March and 30 July 2025, 40 patients were enrolled in the analysis. Following the intervention, the number of patients using one or more brand-name medicines significantly decreased to 25. Knowledge and perceptions of GEs significantly increased after the intervention and were associated with an increased rate of switching to GEs. Binominal logistic regression analysis identified age ≥ 65 years as a strong factor associated with preference for brand-name medicines (OR, 16.45; 95% CI, 1.48–182.65; p = 0.02). These findings indicate that pharmacist-led educational interventions are effective in promoting GE use among patients who prefer brand-name medicines. In the future, we plan to conduct comparative studies with a control group to further investigate the factors that lead to patients strongly preferring the use of brand-name medicines.

  • Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study

    by Hiroaki Takahashi, Yoko Saito, Kanon Sugawara, Masaki Sato, Tomohiko Tairabune, Haruki Ujiie, Junichi Asaka, Kenzo Kudo

    Purpose Acneiform rash is frequently observed in patients undergoing cancer treatment with anti-epidermal growth factor receptor (EGFR) antibody drugs and can often necessitate treatment discontinuation. However, the specific changes in skin parameters resulting from anti-EGFR antibody drug administration are poorly understood. Therefore, this study aimed to longitudinally and quantitatively evaluate the changes in skin parameters (transepidermal water loss [TEWL], hydration level, and sebum level) caused by anti-EGFR antibody drugs and investigate their potential as control markers for skin disorders. Methods This prospective study included 12 patients with colorectal cancer who received anti-EGFR antibody drugs for the first time. The assessment items included the grade of acneiform rash and skin parameters (TEWL, hydration level, and sebum level), which were observed for up to 6 weeks after administration of the medication. Results The enrolled patients were classified into two groups based on the grade of acneiform rash caused by anti-EGFR antibody drugs: “Grade 1 and lower,” and “Grade 2 and higher.” The skin parameters were compared between these groups. The results showed that in the “Grade 2 and higher” group, TEWL in the face (at week 2 of administration), chest (baseline, weeks 2 and 6 of administration), and back (at week 2 of administration) were significantly higher than those in the “Grade 1 and lower” group. However, the two groups showed no significant differences in hydration or sebum levels at any time point. Conclusion TEWL can serve as a marker for acneiform rashes induced by anti-EGFR antibody drugs during cancer treatment.